Gordon Schooley Joins Astralis' Board of Directors
April 26 2005 - 7:00AM
PR Newswire (US)
Gordon Schooley Joins Astralis' Board of Directors FAIRFIELD, N.J.,
April 26 /PRNewswire-FirstCall/ -- Astralis Ltd (OTC:ASTR)
(BULLETIN BOARD: ASTR) announced the appointment of Gordon
Schooley, Ph.D. to its Board of Directors. Dr. Schooley will also
serve as a member of Astralis' Medical Advisory Board. Schooley, a
recognized scientist and clinical expert, is currently the Chief
Scientific Officer of SkyePharma, PLC. "It is a pleasure to welcome
Dr. Schooley to the Astralis Board of Directors. His accomplished
background over a period of 33 years in the pharmaceutical field,
including his extensive clinical and product development experience
will provide valuable expertise to Astralis, and will complement
the Astralis team nicely," stated James Sharpe, Chief Executive
Officer. "The addition of Dr. Schooley to the Board also signifies
the resurgence of the cooperation between Astralis and SkyePharma.
We are pleased to have him on our Board, and look forward to his
contributions." Jose O'Daly, M.D., Ph.D., Chief Scientific Officer
and Chairman of the Board of Astralis, said, "We are very pleased
to see the addition of Dr. Schooley, whom I have known since 2001,
to our Board of Directors. His appointment demonstrates the
commitment of both Astralis and SkyePharma to continuing the
development of Psoraxine, our product for the treatment of
Psoriasis. We also welcome Dr. Schooley's advice and guidance as we
work to develop the other products in our pipeline." Dr. Schooley
received his BS and MS degrees in Business and Statistics from
Brigham Young University and his Doctorate degree in Biostatistics
from The University of Michigan School of Public Health. This press
release may contain forward-looking statements regarding Astralis
Ltd. Clinical results may differ materially from those described in
the press release as a result of a number of factors. There can be
no assurance that Psoraxine(R) will be successfully developed or
manufactured, or that final results of human clinical trials will
result in the regulatory approvals required to market products, or
that final regulatory approval will be received in a timely manner,
if at all, or that patient and physician acceptance of this product
will be achieved. Astralis Ltd undertakes no obligation to revise
or update any such forward-looking statement to reflect events or
circumstances after the date of this release. Notes to the Editor
Astralis Ltd, a biotechnology company based in New Jersey, focuses
on the research and development of novel treatments for immune
system disorders and skin diseases. Psoraxine(R), the company's
first product candidate, is an innovative drug under development
for psoriasis, and is based on the discovery of a proprietary
protein extract. For more information, visit Astralis' web site at
http://www.astralisltd.com/. Psoriasis Psoriasis is a chronic,
genetically based remitting and relapsing scaly and inflammatory
skin disorder that affects approximately 3% of the world's
population. Psoriasis symptoms result from the overproduction of
skin induced by blood cells associated with the immune system.
These blood cells are over-stimulated and act as though the skin
was damaged, manufacturing skin cells at a much faster rate than is
required by undamaged skin. The overproduction of skin can cause a
range of symptoms including itchy rash like patches, painful
pustules and massive inflammation. Additional information can be
obtained from: US National Psoriasis Foundation at
http://www.psoriasis.org/ International Federation of Psoriasis
Associations at http://www.ifpa-pso.org/ DATASOURCE: Astralis Ltd
CONTACT: Astralis Ltd, +1-973-227-7168, or fax, +1-973-227-7169,
Web site: http://www.astralisltd.com/
Copyright